Location of Repository

Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer

By Grant K. Hunter, Chandana A. Reddy, Eric A. Klein, Patrick Kupelian, Kenneth Angermeier, James Ulchaker, Nabil Chehade, Andrew Altman and Jay P. Ciezki


Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525 patients treated in 1999 were reviewed to evaluate toxicity. Late GI and GU morbidities were graded according to the RTOG late morbidity criteria. Other factors examined were patient age, BMI, smoking history, and medical co-morbidities. Due to the low event rate for late GU and GI toxicities, a competing risk regression (CRR) analysis was done with death as the competing event. Results. Median follow-up time was 8.5 years. On CRR univariate analysis, only the presence of DM was significantly associated with GU toxicity grade >2 (P = 0.43, HR 2.35, 95% Cl = 1.03–5.39). On univariate analysis, RT and DM were significantly associated with late GI toxicity. On multivariable analysis, both variables remained significant (RT: P = 0.038, HR = 4.71, CI = 1.09–20.3; DM: P = 0.008, HR = 3.81, 95% Cl = 1.42–10.2). Conclusions. Late effects occur with all treatment modalities. The presence of DM at the time of treatment was significantly associated with worse late GI and GU toxicity. RT was significantly associated with worse late GI toxicity compared to PI and RP

Topics: Clinical Study
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3345236
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2005). A .L .Z i e t m a n ,M .L .D e S i l v i o ,J .D .S l a t e re ta l . ,“ C o m p a r i s o n of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial,”
    2. (1988). A class of K-sample tests for comparing the cumulative incidence of a competing risk,”
    3. (2008). A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or 125i permanent implant,”
    4. (2008). B a r o n e ,H .C .Y e h ,C .F .S n y d e re ta l . ,“ L o n g - t e r ma l l -cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis,”
    5. (2010). Causes of death in men with prevalent diabetes and newly diagnosed high-versus favorable-risk prostate cancer,”
    6. (1999). Diabetes mellitus: a predictor for late radiation morbidity,”
    7. (2000). Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy,”
    8. (2008). Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer,”
    9. (2008). Efstathiou et al., “Diabetes and mortalityinmenwithlocallyadvancedprostatecancer:RTOG 92-02,”
    10. (1999). FineandR.J .Gra y ,“ AP r oportionalH azardsM odelforthe Subdistribution of a Competing Risk,”
    11. (2000). Flanders,“Urinaryfunctionandbotherafterradicalprostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the cancer of the prostate strategic urologic research endeavor,”
    12. h o n g ,L .V a nD eP o l l - F r a n s e ,R .M .H o ffman et al., “Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study,”BJUInternational,vol.107,no.8,pp.1223–1231,2011.
    13. (2000). Health outcomes afterprostatectomyorradiotherapyforprostatecancer:results from the prostate cancer outcomes study,”
    14. (2006). Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from
    15. (2010). Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial,”
    16. (2006). Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance onsurvivalinmalecancerpatients:NationalHealthInsurance
    17. (2007). K u p e l i a n ,T .R .W i l l o u g h b y ,C .A .R e d d y ,E .A .K l e i n
    18. (2005). K u p e l i a n ,V .V .T h a k k a r ,D .K h u n t i a ,C .A .R e d d y
    19. (2007). Lessaggressivetreatmentandworseoverall survivalincancer patients with diabetes: a large population based analysis,”
    20. (2005). M i l l e r ,M .G .S a n d a ,R .L .D u n ne ta l . ,“ L o n g - t e r m outcomes among localized prostate cancer survivors: healthrelated quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy,”
    21. (2000). M o h a n ,P .A .K u p e l i a n ,a n dT .R .W i l l o u g h b y , “Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland,”
    22. (2008). M.G.Sanda,R.L.Dunn,J.Michalskietal.,“Qualityoflifeand satisfaction with outcome among prostate-cancer survivors,” New England
    23. (2002). Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial,”
    24. (2006). Radiobiology for the Radiologist,
    25. (1997). S .P e t e r ,a n dG .E .H a n k s ,“ L a t eG Ia n dG Uc o m p l i c a t i o n s in the treatment of prostate cancer,”
    26. (2003). Time course and predictors of symptoms after primary prostate cancer therapy,”JournalofClinicalOncology,vol.21,no.21,pp.3979– 3986,
    27. (2009). Urinary symptom flare in 712 125I prostate brachytherapy patients: longterm follow-Up,”
    28. (2006). Z e l e f s k y ,H .C h a n ,M .H u n t ,Y .Y a m a d a ,A .M .S h i p p y

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.